Cargando…

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China

OBJECTIVE: This study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China. MATERIALS AND METHODS: Cancer drugs marketed before June 30(th), 2021 with publicly available technical review reports for applica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Kexin, Qin, Huli, Feng, Yiman, Che, Hongxi, Ding, Jinxi, Li, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730273/ https://www.ncbi.nlm.nih.gov/pubmed/36504948 http://dx.doi.org/10.3389/fpubh.2022.1062736

Ejemplares similares

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
por: Zhu, Hong, et al.
Publicado: (2022)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Evaluation of the implementation effect of hepatitis C medical insurance reimbursement policy in China: A RWS based on medical institutions
por: Liu, Yiyao, et al.
Publicado: (2023)

An empirical study of the impact of generic drug competition on drug market prices in China
por: Yina, Chen, et al.
Publicado: (2023)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

Health Benefits of Air Quality Improvement: Empirical Research Based on Medical Insurance Reimbursement Data
por: Li, Ding, et al.
Publicado: (2022)

Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
por: Petrusic, Tamara, et al.
Publicado: (2015)

The Linkages Between Reimbursement and Prevention: A Mixed-Methods Approach
por: Zwaagstra Salvado, Ellen, et al.
Publicado: (2021)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples
por: Capozzi, Monica, et al.
Publicado: (2018)

An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making
por: McNaughton, Rhian, et al.
Publicado: (2014)

Urban and individual correlates of subjective well-being in China: An application of gradient boosting decision trees
por: Huang, Xiaoyan, et al.
Publicado: (2023)

Measuring the Market Power of China's Medical Product Exports
por: Wu, Wanshan, et al.
Publicado: (2022)

Impact of a Restriction in Reimbursement on Proton Pump Inhibitors in Patients with an Increased Risk of Gastric Complications
por: Flinterman, Linda E., et al.
Publicado: (2018)

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
por: Lee, SungKyung, et al.
Publicado: (2023)

Hospitals Visit Intention and Visit Decision: How the Role of Viral and Word of Mouth Marketing?
por: Taufik, E. Rahmat, et al.
Publicado: (2022)

China's Particle Therapy Equipment Market: Opportunities Outweigh Challenges
por: Dai, Zhongying, et al.
Publicado: (2020)

Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II
por: Jakovljevic, Mihajlo, et al.
Publicado: (2023)

The Use of Genotoxicity Endpoints as Biomarkers of Low Dose Radiation Exposure in Interventional Cardiology
por: Habibi, Martha, et al.
Publicado: (2021)

Research on the dynamic spillover of stock markets under COVID-19—Taking the stock markets of China, Japan, and South Korea as an example
por: Zhou, Baicheng, et al.
Publicado: (2022)

Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage
por: Lantzsch, Hendrikje, et al.
Publicado: (2022)

The Reimbursement Rate of New Rural Cooperative Medical Scheme and Self-Rated Health Among Rural Middle-Aged and Elderly
por: Xie, Xingquan, et al.
Publicado: (2022)

Evaluation of whole-genome sequence to predict drug resistance of nine anti-tuberculosis drugs and characterize resistance genes in clinical rifampicin-resistant Mycobacterium tuberculosis isolates from Ningbo, China
por: Che, Yang, et al.
Publicado: (2022)

Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation
por: Naesens, Maarten, et al.
Publicado: (2022)

Prevalence of Visual Impairment in Preschool Children in Southern China
por: Wang, Hongxi, et al.
Publicado: (2022)

Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China
por: Guan, Xiaodong, et al.
Publicado: (2018)

The Impact of the COVID-19 Pandemic on Consumer Behavior—Evidence From China's Stock Market
por: Lu, Zhou, et al.
Publicado: (2022)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study
por: Son, Kyung-Bok
Publicado: (2021)

Health Endpoint of Exposure to Criteria Air Pollutants in Ambient Air of on a Populated in Ahvaz City, Iran
por: Borsi, Seyed Hamid, et al.
Publicado: (2022)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Correlates of cognitive impairment in the elderly in China: A cross-sectional study
por: Wang, Yuan-yuan, et al.
Publicado: (2022)

Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
por: Jenei, Kristina, et al.
Publicado: (2023)

The Impact of Medical Insurance on Household Stock Market Participation: Evidence From China Household Finance Survey
por: Shi, Gui Fen, et al.
Publicado: (2021)

Shared decision-making in healthcare in mainland China: a scoping review
por: Li, Xuejing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2plhgtdugft7ea1ob4rpernikq